An Open-Label Trial of Donepezil in Fragile X Syndrome
Completed · Phase 1
Conditions studied: Fragile X Syndrome
In brief
Fragile X syndrome is the most common known inherited cause of neurodevelopmental disability. Functional magnetic resonance imaging (fMRI) studies from our laboratory indicate that specific brain regions using the neurochemical, acetylcholine, show significantly reduced activation during learning. Since donepezil is a medication that enhances acetylcholine function in the brain, the purpose of this study is to determine if donepezil has any beneficial effect on behavior or cognition in subjects with fragile X syndrome.
Key facts
- Study ID
- NCT00220584
- Run by
- Stanford University
- People needed
- 10
- Starts
- 2005-07-01
- Expected to finish
- 2009-07-01
- Last updated by the study team
- 2012-12-13
Who can join
Age: 14 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Stanford University School of Medicine — Stanford, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.